• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatitis: Monitoring drug therapy for hepatitis B--a global challenge?

作者信息

Nguyen Tin, Locarnini Stephen

机构信息

Department of Gastroenterology, St Vincent's Hospital, Victoria, Australia.

出版信息

Nat Rev Gastroenterol Hepatol. 2009 Oct;6(10):565-7. doi: 10.1038/nrgastro.2009.160.

DOI:10.1038/nrgastro.2009.160
PMID:19789570
Abstract
摘要

相似文献

1
Hepatitis: Monitoring drug therapy for hepatitis B--a global challenge?
Nat Rev Gastroenterol Hepatol. 2009 Oct;6(10):565-7. doi: 10.1038/nrgastro.2009.160.
2
Treatment of chronic hepatitis B with telbivudine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited.用替比夫定治疗慢性乙型肝炎：在治疗选择有限的乙肝流行国家需要明智的肝病专家。
Liver Int. 2011 May;31(5):589-91. doi: 10.1111/j.1478-3231.2010.02437.x. Epub 2011 Feb 6.
3
The role of HBsAg quantification for monitoring natural history and treatment outcome.HBsAg 定量检测在监测自然史和治疗结局中的作用。
Liver Int. 2013 Feb;33 Suppl 1:125-32. doi: 10.1111/liv.12075.
4
Which Is More Clinically Relevant: End-of-Treatment or Off-Treatment Predictors of Hepatitis B Relapse and Surface Antigen Loss?对于乙肝复发和表面抗原消失而言，治疗结束时还是治疗后预测指标在临床方面更具相关性？
Gastroenterology. 2024 Jun;166(6):1193-1194. doi: 10.1053/j.gastro.2023.10.020. Epub 2023 Oct 26.
5
[Interferon therapy for chronic hepatitis B].[慢性乙型肝炎的干扰素治疗]
Zhonghua Gan Zang Bing Za Zhi. 2009 Oct;17(10):726-9.
6
Changing landscape of antiviral resistance management in chronic hepatitis B.慢性乙型肝炎抗病毒耐药管理的不断变化态势
J Gastroenterol Hepatol. 2008 Sep;23(9):1314-7. doi: 10.1111/j.1440-1746.2008.05551.x.
7
Early hepatitis B viral DNA clearance predicts treatment response at week 96.早期乙型肝炎病毒 DNA 清除可预测第 96 周的治疗应答。
World J Gastroenterol. 2017 Apr 28;23(16):2978-2986. doi: 10.3748/wjg.v23.i16.2978.
8
Hepatitis B e antigen as a predictor for hepatitis B e antigen-positive chronic hepatitis B patients with peginterferon alfa-2a therapy.乙肝e抗原作为聚乙二醇干扰素α-2a治疗乙肝e抗原阳性慢性乙型肝炎患者的预测指标。
Hepatology. 2009 Nov;50(5):1677; author reply 1677-9. doi: 10.1002/hep.23018.
9
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎期间，HBeAg和乙肝病毒DNA作为疗效预测指标
Hepatology. 2008 Feb;47(2):428-34. doi: 10.1002/hep.22065.
10
Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients.预测慢性乙型肝炎患者对α干扰素治疗产生乙肝e抗原血清学转换的模型
World J Gastroenterol. 2015 May 14;21(18):5668-76. doi: 10.3748/wjg.v21.i18.5668.

引用本文的文献

1
Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients.HBV DNA 加 RNA 在 HBeAg 阳性 CHB 患者 NAs 治疗前后反映 cccDNA 水平。
Int J Med Sci. 2022 May 9;19(5):858-866. doi: 10.7150/ijms.71737. eCollection 2022.
2
Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs.血清 HBV RNA 在核苷（酸）类似物时代慢性乙型肝炎抗病毒治疗中的潜在应用。
Front Med. 2017 Dec;11(4):502-508. doi: 10.1007/s11684-017-0590-z. Epub 2017 Nov 23.
3
Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

本文引用的文献

1
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.基线特征和早期治疗反应可预测替比夫定治疗慢性乙型肝炎2年的疗效。
J Hepatol. 2009 Jul;51(1):11-20. doi: 10.1016/j.jhep.2008.12.019. Epub 2009 Feb 12.
2
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.乙肝病毒表面抗原水平：HBeAg阴性慢性乙型肝炎患者对聚乙二醇干扰素α-2a持续应答的指标
Hepatology. 2009 Apr;49(4):1141-50. doi: 10.1002/hep.22760.
3
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.
乙型肝炎病毒在肝细胞中持续存在的机制及其致癌潜力
Clin Infect Dis. 2016 Jun 1;62 Suppl 4(Suppl 4):S281-8. doi: 10.1093/cid/ciw023.
4
Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b.聚乙二醇干扰素 alfa-2b 治疗慢性乙型肝炎患者的血清蛋白。
World J Gastroenterol. 2013 Aug 21;19(31):5067-75. doi: 10.3748/wjg.v19.i31.5067.
5
Phase diagrams map the properties of antiviral agents directed against hepatitis B virus core assembly.相图描绘了针对乙型肝炎病毒核心组装的抗病毒药物的特性。
Antimicrob Agents Chemother. 2013 Mar;57(3):1505-8. doi: 10.1128/AAC.01766-12. Epub 2012 Dec 3.
长期监测显示，初治患者在接受5年恩替卡韦治疗期间，对该药物产生乙肝病毒耐药的情况罕见。
Hepatology. 2009 May;49(5):1503-14. doi: 10.1002/hep.22841.
4
EASL Clinical Practice Guidelines: management of chronic hepatitis B.欧洲肝脏研究学会临床实践指南：慢性乙型肝炎的管理
J Hepatol. 2009 Feb;50(2):227-42. doi: 10.1016/j.jhep.2008.10.001. Epub 2008 Oct 29.
5
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎期间，HBeAg和乙肝病毒DNA作为疗效预测指标
Hepatology. 2008 Feb;47(2):428-34. doi: 10.1002/hep.22065.
6
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.预测聚乙二醇干扰素α-2a、拉米夫定及两者联合用药对HBeAg阴性慢性乙型肝炎的疗效
Gut. 2007 May;56(5):699-705. doi: 10.1136/gut.2005.089722. Epub 2006 Nov 24.
7
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.基于循环乙肝病毒载量水平预测肝硬化风险。
Gastroenterology. 2006 Mar;130(3):678-86. doi: 10.1053/j.gastro.2005.11.016.
8
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.血清乙型肝炎病毒DNA水平生物梯度上肝细胞癌的风险。
JAMA. 2006 Jan 4;295(1):65-73. doi: 10.1001/jama.295.1.65.
9
Lamivudine for patients with chronic hepatitis B and advanced liver disease.拉米夫定用于慢性乙型肝炎和晚期肝病患者。
N Engl J Med. 2004 Oct 7;351(15):1521-31. doi: 10.1056/NEJMoa033364.